Engitix Therapeutics
Ifigeneia Bardi has a wealth of work experience in the field of science. In 2021, they began working as a Scientist at Engitix Therapeutics. From 2016 to 2021, they held various roles at Imperial College London, including Graduate Teaching Assistant, Researcher PhD Student, and Postdoctoral Researcher, where they studied the effect of Mesenchymal Stem Cell (BM-MSC) derived exosomes on endothelial cell regeneration. Ifigeneia also optimised the MSC culture system using mini-bioreactor systems, isolated and characterised the secreted exosomes and validated their effect using biochemical assays and confocal microscopy. In 2014, they held a Placement Student position at Theageneio, Anticancer Hospital of Thessaloniki.
Ifigeneia Bardi completed their Bachelor's degree in Molecular and Developmental Biology at Aristotle University of Thessaloniki (AUTH) between 2010 and 2015. Ifigeneia then went on to complete a Master's degree in Advanced Therapies-Genes, Drugs and Stem Cells at Imperial College London in 2016. Finally, they completed their Doctor of Philosophy - PhD in Cardiovascular research at Imperial College London in 2020.
Engitix Therapeutics
To create a healthier future for patients with life-threatening diseases, Engitix Therapeutics is using its pioneering human extracellular matrix (ECM)-based discovery platform to develop a portfolio of programmes in fibrosis and solid tumors.